TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

Microsoft's CEO, Satya Nadella, has announced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding ...

Satya Nadella has unveiled BioEmu, Microsoft's new AI initiative aimed at accelerating drug discovery processes.

Microsoft's BioEmu, an AI-driven model, decodes protein motion to enhance drug discovery, offering rapid insights into ...

Centella AI streamlines drug discovery using AI-powered platforms, reducing R&D time and cost with real-world scientific validation ...

Understanding protein motion is essential to understanding biology and advancing drug discovery,” said Nadella, in a post on ...

Revolution Medicines' proprietary data will train a bespoke version of NeuralPLexer, an AI model for protein-ligand ...

The start-up, which aims to raise tens of millions of US dollars in an angel funding round, hopes to compete globally, ...

Drug discovery startup Synfini Inc. said today it has closed on an $8.9 million expansion funding round led by JSL Health ...

Microsoft’s new AI system BioEmu will help decode protein motion and help in faster discovery of drugs, said CEO Satya ...

Researchers discovered how to flip the structure of complex drug compounds using a simple reagent, offering a game-changing ...

Revolution Medicines has zeroed in on Iambic Therapeutics’ AI drug discovery platform, striking a multi-year technology and research collaboration that gives Iambic the chance to earn up to $25 mil | ...